Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 5/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655254 | 0.95 | ALDH1A1 (0.68) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL6383063 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL14088979 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL14088978 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL13593340 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL664024 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| Salcaprozic Acid SCHEMBL4586235 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL2331916 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| Salcaprozic Acid SCHEMBL29385752 | 0.94 | NAAA (0.70) | NPC1ALDH1A1MAPTHPGDTSHR | |
| Salcaprozic Acid SCHEMBL845833 | 0.92 | NAAA (0.68) | NPC1ALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755578-B2 | CHEWABLE, SUCKABLE AND SWALLOWABLE TABLET CONTAINING A CALCIUM-CONTAINING COMPOUND AS AN ACTIVE SUBSTANCE | TAKEDA AS (NO) | 2018-11-28 | — | — | EP | disclosed |
| US-9801907-B2 | Film-coated and/or granulated calcium-containing compounds and use therof in pharmaceutical compositions | TAKEDA AS (NO) | 2017-10-31 | — | — | US | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150050353-A1 | FILM-COATED AND/OR GRANULATED CALCIUM-CONTAINING COMPOUNDS AND USE THEROF IN PHARMACEUTICAL COMPOSITIONS | TAKEDA AS (NO) | 2015-02-19 | — | — | US | disclosed |
| US-8846088-B2 | Melt granulation of a composition containing a calcium-containing compound | TAKEDA NYCOMED AS (NO) | 2014-09-30 | — | — | US | disclosed |
| US-8846101-B2 | Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions | TAKEDA NYCOMED AS (NO) | 2014-09-30 | — | — | US | disclosed |
| US-8808735-B2 | Fast wet-massing method for the preparation of calcium-containing compositions | TAKEDA NYCOMED AS (NO) | 2014-08-19 | — | — | US | disclosed |
| EP-1755578-A2 | CHEWABLE, SUCKABLE AND SWALLOWABLE TABLET CONTAINING A CALCIUM-CONTAINING COMPOUND AS AN ACTIVE SUBSTANCE | Nycomed Pharma AS (NO) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006092727-A9 | PROCESS FOR THE PRODUCTION OF CALCIUM COMPOSITIONS IN A CONTINUOUS FLUID BED | NYCOMED PHARMA AS (NO) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006092727-A2 | PROCESS FOR THE PRODUCTION OF CALCIUM COMPOSITIONS IN A CONTINUOUS FLUID BED | NYCOMED PHARMA AS (NO) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006082499-A1 | MELT GRANULATION OF A COMPOSITION CONTAINING A CALCIUM-CONTAINING COMPOUND | NYCOMED PHARMA AS (NO) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082501-A2 | FAST WET-MASSING METHOD FOR THE PREPARATION OF CALCIUM-CONTAINING COMPOSITIONS | NYCOMED PHARMA AS (NO) | 2006-08-10 | — | — | WO | disclosed |
| CN-1816324-A | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use | NYCOMED DANMARK APS (DK) | 2006-08-09 | — | — | CN | disclosed |
| WO-2006046111-A1 | USE OF XYLITOL AS AN ANTI-CHALK ACTING AGENT IN COMPOSITIONS FOR ORAL USE CONTAINING A CALCIUM-CONTAINING COMPOUND AS AN ACTIVE SUBSTANCE | NYCOMED PHARMA AS (NO) | 2006-05-04 | — | — | WO | disclosed |
| EP-1643978-A1 | PARATHYROID HORMONE (PTH) CONTAINING PHARMACEUTICAL COMPOSITIONS FOR ORAL USE | NYCOMED DANMARK A/S (DK) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005117829-A2 | CHEWABLE, SUCKABLE AND SWALLOWABLE TABLET CONTAINING A CALCIUM-CONTAINING COMPOUND AS AN ACTIVE SUBSTANCE | NYCOMED PHARMA AS (NO) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005002549-A1 | PARATHYROID HORMONE (PTH) CONTAINING PHARMACEUTICAL COMPOSITIONS FOR ORAL USE | NYCOMED DANMARK APS (DK) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | NPC1 506/4885ALDH1A1 3386/4885MAPT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.